Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.68 |
| ▸ | KDM4A | O75164 | 3/20 | 0.68 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
| ▸ | HIF1AN | Q9NWT6 | 1/20 | 0.68 |
| ▸ | PSMD14 | O00487 | 2/20 | 0.64 |
| ▸ | KDM6B | O15054 | 2/20 | 0.54 |
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.54 |
| ▸ | KDM6A | O15550 | 1/20 | 0.54 |
| ▸ | TET3 | O43151 | 1/20 | 0.54 |
| ▸ | KDM4B | O94953 | 1/20 | 0.54 |
| ▸ | KDM5C | P41229 | 1/20 | 0.54 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.54 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.54 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.54 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.54 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.54 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15757867 | 0.86 | KDM4E (0.68) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL30553415 | 0.85 | KDM4E (0.51) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL27214228 | 0.85 | KDM4E (0.51) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL69905 | 0.84 | KDM4E (0.74) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL11973493 | 0.81 | PSMD14 (0.68) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL298623 | 0.81 | KDM4E (1.00) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL23754369 | 0.79 | EGLN1 (0.50) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL7373143 | 0.79 | KDM4E (0.68) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL23812284 | 0.79 | NR4A2 (0.54) | KDM4EL3MBTL1KDM4AEGLN1RAB9A | |
| SCHEMBL15129840 | 0.79 | KDM4E (0.68) | KDM4EL3MBTL1KDM4AEGLN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025085689-A1 | EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | claimed |
| CN-122094950-A | Ligand compound with quinoline structure, and radioactive or non-radioactive marker and application thereof | — | 2026-05-26 | — | — | CN | disclosed |
| WO-2026103814-A1 | IRREVERSIBLE FAP INHIBITOR AND USE THEREOF | 南京科络思生物科技有限公司 | 2026-05-21 | — | — | WO | disclosed |
| WO-2026098607-A1 | F-18 LABELED AQUEOUS PHARMACEUTICAL COMPOSITION TARGETING LIGAND OF FIBROBLAST ACTIVATION PROTEIN, AND PREPARATION METHOD THEREFOR | 天津恒瑞医药有限公司 | 2026-05-15 | — | — | WO | disclosed |
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | TRUSTEES OF TUFTS COLLEGE | 2026-01-08 | — | — | US | disclosed |
| EP-4584256-A1 | MULTIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | Philochem AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| US-20250177582-A1 | HIGH-AFFINITY LIGANDS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2025-06-05 | — | — | US | disclosed |
| WO-2025087229-A1 | LIGAND COMPOUND OF QUINOLINE STRUCTURE, RADIOACTIVE OR NON-RADIOACTIVE MARKER, AND USE | 四川科伦博泰生物医药股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| WO-2025087466-A2 | LIGAND COMPOUND OF QUINOLINE STRUCTURE, AND RADIOACTIVE OR NON-RADIOACTIVE MARKER THEREOF AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2025-05-01 | — | — | WO | disclosed |
| WO-2025085689-A1 | EXTRACELLULAR SMALL MOLECULE ACTIVATORS TARGETING BESTROPHIN CHANNELS FOR DISEASE TREATMENT | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2025-04-24 | — | — | WO | disclosed |
| WO-2022171811-A1 | BIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2022-08-18 | — | — | WO | disclosed |
| EP-4043452-A1 | BIVALENT FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | Philochem AG (CH) | 2022-08-17 | — | — | EP | disclosed |
| EP-4019507-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | Philochem AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-4019507-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | Philochem AG (CH) | 2022-06-29 | — | — | EP | disclosed |
| EP-3891138-B1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2022-01-12 | — | — | EP | disclosed |
| EP-3891138-B1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2022-01-12 | — | — | EP | disclosed |
| EP-3891138-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | Philochem AG (CH) | 2021-10-13 | — | — | EP | disclosed |
| WO-2021160825-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2021-08-19 | — | — | WO | disclosed |
| WO-2021160825-A1 | FIBROBLAST ACTIVATION PROTEIN LIGANDS FOR TARGETED DELIVERY APPLICATIONS | PHILOCHEM AG (CH) | 2021-08-19 | — | — | WO | disclosed |
| CN-103492028-A | Novel sulfonaminoquinoline hepcidin antagonists | VIFOR INT AG | 2014-01-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007787-A1 | RADIOPHARMACEUTICAL SMALL MOLECULE INHIBITORS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED THERAPY AND DIAGNOSTIC IMAGING OF DESMOPLASTIC TUMORS | FIBP, FRS2, FGFR1 | KDM4E 2776/4885L3MBTL1 2529/4885KDM4A 3215/4885 |
| US-20250177582-A1 | HIGH-AFFINITY LIGANDS OF FIBROBLAST ACTIVATION PROTEIN FOR TARGETED DELIVERY APPLICATIONS | FAP, FIBP, FGFR1 | KDM4E 4141/4885L3MBTL1 3559/4885KDM4A 3861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.